Interestingly, in our analysis correlating SNRPD2 expression to anti-tumor drug sensitivity on a large panel of human cancer cell lines, we observed that cancer cells that were sensitive to treatment with several FDA-approved targeted drugs expressed higher SNRPD2 levels than resistant cancer cells. The gene discussed is SNRPD2; the disease is neoplasm.